A retrospective study comparing the results of continuous glucose monitoring to self-blood glucose monitoring for pregnant women with type 1 diabetes mellitus.

IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM

Expert Review of Endocrinology & Metabolism Pub Date : 2024-09-01 Epub Date: 2024-05-13 DOI:10.1080/17446651.2024.2354471

Adeel Ahmad Khan, Fateen Ata, Naglaa Abdelaleem Al Sayed Alsharkawy, Eman Mahmoud Mohamed Othman, Ifrah Mohamed Hassan, Faten Altaher Mohd Taha, Khaled Baagar, Hamda Ali, Jutin C Konje, Abdul Badi Abou-Samra, Mohammed Bashir

{"title":"A retrospective study comparing the results of continuous glucose monitoring to self-blood glucose monitoring for pregnant women with type 1 diabetes mellitus.","authors":"Adeel Ahmad Khan, Fateen Ata, Naglaa Abdelaleem Al Sayed Alsharkawy, Eman Mahmoud Mohamed Othman, Ifrah Mohamed Hassan, Faten Altaher Mohd Taha, Khaled Baagar, Hamda Ali, Jutin C Konje, Abdul Badi Abou-Samra, Mohammed Bashir","doi":"10.1080/17446651.2024.2354471","DOIUrl":null,"url":null,"abstract":"Background: Type 1 diabetes mellitus (T1DM) is associated with adverse maternal and fetal outcomes. Continuous glucose monitoring (CGM) during pregnancy is associated with better glycemic control in women with T1DM. However, no clear benefits have been demonstrated in reducing adverse feto-maternal outcomes in pregnant women with T1DM.Design and methods: This is a retrospective, single-center study of pregnant women with T1DM to evaluate the impact of CGM use on glycemic control and feto-maternal outcomes in pregnant women with T1DM.Results: Of 265 women with T1DM, 92 (34.7%) used CGM, and 173 (65.3%) were managed with capillary blood glucose (CBG) monitoring. The mean (SD) age and BMI at the first visit were 29.4 (4.7) years and 27.2 (5.2) kg/m2, respectively. The mean (SD) HbA1c at the first-trimester visit was 63 (1) mmol/mol, and in the last trimester was 51 (1%). There was no difference in the mean changes in HbA1c between the two groups. Women using CGM had lower insulin requirements (1.02 + 0.37 vs. 0.87 + 0.04 units/kg, p = 0.01). The two groups had no significant differences in maternal or fetal outcomes.Conclusion: CGM use in pregnant T1DM women is not associated with improved fetomaternal outcomes.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17446651.2024.2354471","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Type 1 diabetes mellitus (T1DM) is associated with adverse maternal and fetal outcomes. Continuous glucose monitoring (CGM) during pregnancy is associated with better glycemic control in women with T1DM. However, no clear benefits have been demonstrated in reducing adverse feto-maternal outcomes in pregnant women with T1DM.

Design and methods: This is a retrospective, single-center study of pregnant women with T1DM to evaluate the impact of CGM use on glycemic control and feto-maternal outcomes in pregnant women with T1DM.

Results: Of 265 women with T1DM, 92 (34.7%) used CGM, and 173 (65.3%) were managed with capillary blood glucose (CBG) monitoring. The mean (SD) age and BMI at the first visit were 29.4 (4.7) years and 27.2 (5.2) kg/m^2, respectively. The mean (SD) HbA1c at the first-trimester visit was 63 (1) mmol/mol, and in the last trimester was 51 (1%). There was no difference in the mean changes in HbA1c between the two groups. Women using CGM had lower insulin requirements (1.02 + 0.37 vs. 0.87 + 0.04 units/kg, p = 0.01). The two groups had no significant differences in maternal or fetal outcomes.

Conclusion: CGM use in pregnant T1DM women is not associated with improved fetomaternal outcomes.

查看原文本刊更多论文

一项回顾性研究，比较了对 1 型糖尿病孕妇进行连续血糖监测和自我血糖监测的结果。

背景：1 型糖尿病（T1DM）与孕产妇和胎儿的不良结局有关。孕期连续血糖监测（CGM）可改善 T1DM 孕妇的血糖控制。然而，在减少 T1DM 孕妇对胎儿和母体的不良影响方面并没有明显的益处：这是一项针对 T1DM 孕妇的单中心回顾性研究，旨在评估 CGM 的使用对 T1DM 孕妇血糖控制和胎儿-产妇结局的影响：在 265 名 T1DM 孕妇中，92 人（34.7%）使用了 CGM，173 人（65.3%）接受了毛细血管血糖 (CBG) 监测。首次就诊时的平均（标清）年龄和体重指数分别为 29.4 (4.7) 岁和 27.2 (5.2) kg/m2。首次就诊时的 HbA1c 平均值（标清）为 63 (1) mmol/mol，最后三个月为 51 (1%)。两组 HbA1c 的平均变化没有差异。使用 CGM 的妇女胰岛素需求量较低（1.02 + 0.37 vs. 0.87 + 0.04 单位/公斤，p = 0.01）。两组孕妇和胎儿的结局无明显差异：结论：T1DM 孕妇使用 CGM 与改善胎儿和产妇预后无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Endocrinology & Metabolism ENDOCRINOLOGY & METABOLISM-

CiteScore

4.80

自引率

0.00%

发文量

期刊介绍： Implicated in a plethora of regulatory dysfunctions involving growth and development, metabolism, electrolyte balances and reproduction, endocrine disruption is one of the highest priority research topics in the world. As a result, we are now in a position to better detect, characterize and overcome the damage mediated by adverse interaction with the endocrine system. Expert Review of Endocrinology and Metabolism (ISSN 1744-6651), provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology.